{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-23-000024","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.266169+00:00","generated_at":"2026-06-15T21:47:40.860705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroPace Q1 revenue $14.5M (+27% YoY) and raises FY2023 guidance to $52-54M","bullets":["Q1 revenue $14.5M, up 27% YoY and 13% sequentially; net loss narrowed to $10.4M from $11.5M.","Full-year 2023 revenue guidance raised to $52-54M (prior $50-52M), implying 14-19% YoY growth.","Gross margin 72% vs 73% YoY; operating expenses $18.7M; cash and investments $67.6M.","RNS System utilization and DIXI Medical distribution drove growth; replacement implants declined.","NAUTILUS pivotal study for primary generalized epilepsy enrolling as expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-23-000024","json":"https://secwatch.observer/filing/0001528287-23-000024.json","markdown":"https://secwatch.observer/filing/0001528287-23-000024.md","text":"https://secwatch.observer/filing/0001528287-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/npce-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:47:40.860705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bac80aa409a91c658355b3bf400294f4085a306","claim":"NeuroPace Inc reported full year 2023 results: revenue $52 million to $54 million. Guidance raised.","evidence_excerpt":"Full Year 2023 Financial Guidance • Increased total revenue guidance to $52 million to $54 million, representing growth of 14% to 19% over 2022, as compared to previously-communicated guidance of $50 million to $52 million • Reiterated gross margin to range between 69% and 71% • Reiterated total operating expenses to range between $75 million and $77 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$52 million to $54 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6749ff633573022a5a16a93e459319991df27b24","claim":"NeuroPace Inc reported first quarter ended March 31, 2023 results: revenue $14.5 million, net income $10.4 million.","evidence_excerpt":"Total revenue was $14.5 million in the first quarter of 2023, representing growth of 27% compared to the prior year period and 13% compared to the prior quarter. Replacement implant revenue declined compared to the prior year period and represented less than 10% of total revenue in the first quarter of 2023. The decrease in replacement implant revenue was expected as previously implanted patients finish transitioning to the second generation RNS System with a nearly 11-year average battery life. Gross margin for the first quarter of 2023 was 72% compared to 73% in the first quarter of 2022 and 69% in the fourth quarter of 2022. The decline in gross margin compared to the first quarter of 2022 was primarily due to the change in product mix as a result of initiating distribution of DIXI Medical products in the fourth quarter of 2022. Total operating expenses in the first quarter of 2023 were $18.7 million, compared to $18.0 million in the prior year period. R&D expense in the first quart","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$14.5 million"},{"label":"Net income","value":"$10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}